Generated by AI
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s current work centers on cancer treatments that act on the PAM pathway, including its lead therapeutic candidate gedatolisib, which is being developed for advanced breast cancer and metastatic castration-resistant prostate cancer. Celcuity also operates a cellular analysis platform used to identify abnormal signaling activity in tumors and help guide the development of precision oncology therapies. Its business is concentrated in oncology drug development, with programs aimed at patients whose cancers are driven by specific molecular pathways. Headquartered in Minneapolis, Minnesota, Celcuity is positioned as a research-driven biotech company working across therapeutic development and biomarker-based cancer analysis.
Website2800 Campus Drive
Minneapolis, MN, 55441
United States
The latest articles about CELC.
Summary of Nov 16's posts. Generated by AI.
Summary of Jul 15's posts. Generated by AI.
Summary of Jul 28's posts. Generated by AI.
Summary of Oct 24's posts. Generated by AI.
Investors talking about CELC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.